Project Grant R01CA292377
Award Date
6/23/25
Completion Date
5/31/30
Dollars Obligated
$627K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $727,732 to conduct research aimed at overcoming resistance to CDK4/6 inhibitor therapy for patients with dedifferentiated liposarcoma. The key products and services to be delivered include: (1) conducting a Phase Ib/II clinical trial to evaluate the efficacy of combining the CDK4/6 inhibitor palbociclib with the MEK inhibitor...
The University of Miami was awarded a $447,340 Project Grant by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to investigate epigenetic mechanisms and vulnerabilities in endocrine-resistant breast cancer. The 5-year grant, starting on March 1, 2025, aims to identify novel therapeutic targets and improve survival rates for patients with metastatic, endocrine-resistant estrogen receptor positive (ER+) breast cancer. The research will focus on the role of the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center provides $449,196.00 to conduct research on mechanisms of resistance to tyrosine kinase inhibitor (TKI) therapies in cancer. The key focus is investigating how TKI treatment induces sumoylation (a post-translational modification) of receptor tyrosine kinases (RTKs), which then act as adaptor proteins to drive therapeutic resistance through...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms driving acquired cross-resistance in small cell lung cancer (SCLC). The $642,429 award to the University of Texas Southwestern Medical Center, effective January 1, 2025 through December 31, 2029, aims to investigate how extrachromosomal MYC amplifications contribute to broad chemotherapy resistance in SCLC patient-derived...
The National Cancer Institute (NCI) awarded a $303,112 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Virginia Commonwealth University (VCU) on September 30, 2024. The grant supports research to evaluate the efficacy of the FDA-approved drug elacestrant versus standard of care in preclinical models of estrogen receptor-positive (ER+) breast cancer bone metastasis. The project will utilize in vitro, in vivo, and ex vivo models to assess elacestrant's impact on...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $248,999 to Case Western Reserve University to support research on the regulation of the CDK4/CDH1/PIN1 signaling axis for developing targeted breast cancer therapies. The key objectives are to: 1) explore the role of the CDK4 kinase in regulating the E3 ligase activity of CDH1, and 2) investigate the potential for CDH1 to mediate PIN1 inhibitor-induced degradation of...
The federal Project Grant award K01CA297135, funded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research to determine the impact of CDK4/6 inhibition on the progression of intraductal papillary mucinous neoplasms (IPMNs) - common precancerous pancreatic cystic lesions that may progress to pancreatic ductal adenocarcinoma. The $166,037 award to the University of California, San Diego (UCSD) will fund preclinical studies in...
This Project Grant award, valued at $567,059.00, was awarded on March 17, 2025 by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The award supports research conducted by the University of Texas MD Anderson Cancer Center to investigate the potential synergy between the CDK4/6 inhibitor abemaciclib and the silencing of circular RNAs (circRNAs) in enhancing anti-tumor immune responses for soft-tissue sarcomas (STS). The key focus areas include: 1)...
The National Cancer Institute awarded a $340,072 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant supports research to evaluate TMU27A, a novel non-nucleoside ribonucleotide reductase (RNR) inhibitor, as a potential treatment for metastatic breast cancer. Proposed studies will investigate TMU27A's impact on genome stability, efficacy, and safety compared to the current RNR...
This Project Grant award of $1,635,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports research at the University of Texas MD Anderson Cancer Center to investigate a novel approach to combat breast cancer brain metastasis. Specifically, the research aims to target the PCTK1 driver kinase in combination with ferroptosis inducers. This innovative therapeutic strategy has the potential to...